Mexico – AMLO Popular, but Not Invulnerable

Approaching the two-year mark of his six-year term as president, Andrés Manuel López Obrador (aka AMLO) remains broadly popular, despite a thin record of accomplishments and deservedly poor reviews from critics of his handling of the COVID-19 pandemic and the related economic difficulties. While Read Entire Entry

Belgium – Broad Coalition Formed

In early October, some 21 months after the collapse of Charles Michel’s center-right government in December 2018, and more than 16 months on from a general election held in May 2019, the Parliament confirmed a new majority government made up of the liberal, socialist, and green parties Read Entire Entry

Regional Political Risk Index (October 2020)

Below is our most recent Political Risk Index (PRI) Table ranked from low to high risk within each region listed. The PRI is the overall measure of risk for a given country, calculated by using all 17 risk components from the PRS Methodology including turmoil, financial transfer, direct investment, Read Entire Entry

Coming Soon in Our December 2020 Political Risk Reports

PRS’ coverage of the Americas this month includes post-election analyses of Jamaica and the Dominican Republic, along with an in-depth look at how next year’s elections figure to affect risk in Ecuador, where the outgoing government secured a lending agreement with the IMF that will enable it Read Entire Entry

Hungary – EU Raises the Stakes

A victory for the main governing Fidesz in a parliamentary by-election held on October 11 has raised doubts about the feasibility of the opposition’s proposed strategy of forming a big-tent electoral alliance and fielding joint candidates for all 199 seats in the National Assembly. Moreover, by Read Entire Entry

From the CEO – November 2020

Christopher McKee, PhD, Chief Executive of The PRS Group, Inc.
Dear Clients, The release of some positive news on the vaccine front in November was especially constructive for the emerging and frontier markets in our ICRG coverage. Given concerns among many about the feasibility of storing the vaccines developed by Pfizer and Moderna (which require extremely Read Entire Entry